Published in Cancer Weekly, May 1st, 1995
LMI is a proprietary therapeutic approach designed to stimulate the body's own defense mechanisms against cancer cells and virus-infected cells. In pre-clinical studies, LMI has been shown to effectively stimulate and enhance the responses of cancer specific cytotoxic T lymphocytes (CTL), or "killer cells," against a variety of tumors in mice.
When combined with traditional chemotherapy, the LMI technology significantly improved survival rates of cancer-bearing mice. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.